Streetbeat News

Products Services

LEGN

Legend Biotech Corporation (NASDAQ:LEGN) announced FDA approval of CARVYKTI for second-line treatment of multiple myeloma, making it the first and only BCMA-targeted CAR-T cell therapy for this indication. The approval is based on the CARTITUDE-4 study showing significant improvement in progression-free survival compared to standard treatments. This marks a potential paradigm shift in multiple myeloma treatment, offering a personalized immunotherapy option earlier in the treatment regimen. The safety profile of CARVYKTI includes several warnings, and the company has expanded production capacity to meet demand.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:42 am

BYDDF

GEELY

TSLA

China's Commerce Minister, Wang Wentao, countered claims that the country's EV industry growth is due to subsidies, attributing it instead to 'constant innovations'. During a roundtable in Paris with companies like Geely, BYD, and CATL, Wang addressed the EU's anti-subsidy probe and U.S. concerns about overcapacity. The discussion highlights the global competition and scrutiny of China's EV market, amidst developments like Chery Auto's new EV brand and BYD's potential entry into the EV pickup market.

Portfolio Pulse from Benzinga Neuro

April 08, 2024 | 7:42 am

300750.SZ

BYDDF

GEELY

China's Commerce Minister, Wang Wentao, attributes the success of China's EV industry to 'constant innovations' rather than subsidies, countering U.S. and EU concerns of overcapacity. The comments were made during a roundtable in Paris, involving major Chinese companies like Geely, BYD, and CATL. This comes amidst the EU's anti-subsidy probe into Chinese EV imports and U.S. Treasury Secretary Janet Yellen's visit to China, where she voiced concerns over Chinese industrial overcapacity.

Portfolio Pulse from Benzinga Neuro

April 08, 2024 | 7:41 am

JNJ

The U.S. FDA has approved Johnson & Johnson's CARVYKTI® for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. This approval, based on the Phase 3 CARTITUDE-4 study, shows a 59% reduction in disease progression or death risk compared to standard therapies, marking a significant advancement in treatment options.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:30 am

OCUL

Ocular Therapeutix announced positive Phase 2 data for PAXTRAVA in treating glaucoma, showing significant IOP reductions and good tolerance, at the ASCRS 2024 Annual Meeting. The data suggests potential for repeat dosing due to consistent durability and bioresorption of the implant.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:27 am

CALT

Calliditas Therapeutics AB (NASDAQ:CALT) has received a Notice of Allowance from the USPTO for a patent application covering the use of setanaxib in cancer treatment, specifically for treating solid tumors resistant to PD-1 inhibitor immunotherapy. The anticipated patent expiration date is 2038.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:25 am

TEVA

Teva Pharmaceuticals presented new pharmacokinetic modeling data for UZEDY, an extended-release injectable suspension for schizophrenia, at SIRS 2024. The data offers insights into dosing conversions for switching from a long-acting injectable formulation of risperidone. Additional data from the Phase 3 RISE trial reinforces UZEDY's efficacy and safety. The ADVANCE study will provide real-world findings on long-acting injectable utilization from various stakeholders.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:14 am

BMY

Bristol Myers Squibb presented new interim long-term efficacy data from the EMERGENT-4 trial for KarXT in schizophrenia at the 2024 SIRS Congress, showing continued improvements in symptoms at 52 weeks, with over 75% of participants achieving more than 30% improvement.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:11 am

SHLT

SHL Telemedicine Ltd. (NASDAQ:SHLT) showcased its SmartHeart portable 12-lead ECG technology at the U.S. Army's Project Convergence – Capstone 4 (PC-C4), the largest field experiment to date. SmartHeart was used in various trauma care levels in the Mojave Desert, demonstrating its reliability and effectiveness in extreme conditions. This inclusion highlights SHL's technology as a significant innovation in military healthcare.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:04 am

AMRN

New analyses of the REDUCE-IT study by Amarin demonstrate that its drug VASCEPA/VAZKEPA benefits high-risk cardiovascular disease patient subgroups. This could potentially enhance the drug's market position and appeal to a broader patient base.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:04 am